Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and efficacy of Org 25969 (sugammadex) in cardiac patients
2005-002000-42Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Mar 2006
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of Sugammadex in coronary arteriosclerosis, chronic heart failure (CHF), arrhythmia, sponsored by Organon & Co.. Started Mar 2006; status: completed.
02
Drugs
Sugammadex
03
Conditions
coronary arteriosclerosischronic heart failure (CHF)arrhythmia
Beyond the preview
Go deeper on 2005-002000-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002000-42.